CATEGORY

DNA Sequencing

Use of equipments to decode the genetic seuence employed in drug discovery.

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike DNA Sequencing.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo

DNA Sequencing Industry Benchmarks


Savings Achieved

(in %)

The average annual savings achieved in DNA Sequencing category is 5.40%

Payment Terms

(in days)

The industry average payment terms in DNA Sequencing category for the current quarter is 60.0 days

Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™

Category Strategy and Flexibility

Engagement Model

Supply Assurance

Sourcing Process

Supplier Type

Pricing Model

Contract Length

SLAs/KPIs

Lead Time

Supplier Diversity

Targeted Savings

Risk Mitigation

Financial Risk

Sanctions

AMEs

Geopolitical Risk

Cost Optimization

Price per Unit Competitiveness

Specification Leanness

Minimum Order Quality

Payment Terms

Inventory Control

Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    DNA Sequencing Suppliers


    2,727
    Total Suppliers
    121
    Diverse Suppliers
    73
    Normalized Supplier Rating
    DNA Sequencing Supplier

    Find the right-fit dna sequencing supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    36

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77

    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    DNA Sequencing market report transcript


    DNA Sequencing Landscape

    Supply Market Dynamics

    • The overall next-generation sequencing (NGS) market is growing at a double-digit growth rate owing to increasing applications areas of the NGS clinical segment and the rising number of government genomics projects 

    • NGS service providers enter into strategic partnerships with contract research organizations (CRO)/academics, pharma/biotech, and diagnostic firms to expand their NGS capabilities. Also, collaboration with NGS data analysis firms such as IT firms is on the rise to provide fully integrated NGS service 

    • Government funding for computational genomics encourages advancements in the NGS data analysis sector. For instance, NHGRI, through its Computational Genomics and Data Science Program, funds Genome analysis tools and software resources and data management resources

    NGS Services Spend by End-users and Applications

    • Even though clinical application is growing, the usage of sequencing for research purposes is still dominating the market making academics and research institutions a major end-user

    • NGS services are used along the entire chain from early discovery to clinical trials through predictive biomarkers and patient stratification studies

    • Hospitals and clinics are the fastest-growing end-user segment as clinical NGS shows a great promise to develop in the future

    • Non-clinical segment is also poised to grow with pharmaceutical companies encouraging strategic partnerships with NGS service providers for bringing in patient-specific treatment regimes

    Growth Drivers and Constraints

    Drivers

    Increasing Demand for Clinical NGS

    • The NGS application spectrum is broadening to hospitals and clinics with NGS being performed for diagnosis, treatment and even prevention of diseases. The demand for NGS-based companion diagnostics tools for cancer and infectious diseases is driving the services segment.

    • Next-generation sequencing is seeing huge adoption owing to its lower cost, faster speed, and greater accuracy compared to conventional technologies. Also, the technique requires significantly lesser DNA

    • Moreover, NGS is finding immense use in drug discovery applications and is an effective replacement for traditional technologies.  

    Preference for Outsourcing

    • Not every firm performing sequencing services can offer NGS data analysis, as it is a niche area and requires dedicated bioinformatics team to handle the data analysis service. The niche area of NGS data analysis is driving the NGS services segment as buyers are looking for integrated service providers.

    Diversified NGS Platforms

    • Need for different sequencing platforms for different experiments, as there is no single sequencing platform to perform all set of experiments. The output of each platform is different, which brings in the need for different platforms. Also, the cost of sequencers had drastically reduced in the past few years across major players

    Constraints

    Lack of Skilled Labor

    • The crucial steps of sequencing, such as for sample and library preparation as well as analysis needs expertise. Also, library preparation rely on experience, as it is relatively a manual process and data analysis that involves huge volumes of complex raw data to interpret.

    Surging Cost of NGS Reagents

    • Even though, the NGS platforms rates have reduced considerably, the cost of reagents is surging up Y-o-Y, which increases the overall cost of NGS sequencing.

    Data Accuracy and Standardization

    • Even after the introduction of sophisticated sequencers and better consumables, standardization of NGS data is still a bottleneck to the market growth of NGS platforms

    COVID-19 Impact on DNA Sequencing Market

    • The COVID-19 crisis has triggered the adoption of NGS technology in the diagnosis of infections owing to its optimal accuracy and efficiency. The Food and Drug Administration (FDA) has granted an emergency use approval to Ilumina Inc. for its COVIDSeq test - the first COVID-19 diagnostic kit based on NGS. 

    • The benefit of leveraging an NGS test is that the approach offers information about the presence of the virus as well as its genomic sequence in a sample. This genomic data can be beneficial for research purposes as well thus boding well for the DNA sequencing market size.

    Outsourcing Adoption Rate

    • NGS is outsourced at an approximate rate of 60–65% in 2017. It is mainly driven by high-cost infrastructure and the expertise requirement for NGS services

    • Downsizing by pharma/biotech firms, decreasing research and development funding, and focus on core competencies are the key factors driving outsourcing

    • Though the supplier fee for an outsourced service is high, reduction in fixed costs over the long term is far beneficial

    • Drug discovery and development is still one of the prime areas to be outsourced among the non-clinical application segments. However, clinical application would see a vast increase in outsourcing rate in the upcoming years

    • Pharma and biotech companies are the largest end-user segment that outsources the NGS services to reduce the overall fixed cost and improve the operational efficiency for NGS services

    • Outsourcing enables access to best-in-class technologies through the latest array of sequencers, such as oxford nanopore and also integrated services along with data interpretation and storage

    Changing regulatory scenario, CRO dynamics, risk sharing models, technologies are the key areas impacting early phase trial conduct in the next-generation sequencing market. Buyers have to ensure suppliers have regional regulatory expertise, therapeutic, operational capability and innovative technologies to handle the complex trials. Upon assurance, a full-service strategic partnership could be formed.

    DNA Sequencing Market Trends

    • Changing regulatory scenarios, CRO dynamics, risk-sharing models, technologies are the key areas impacting early-phase trials conducted in the next-generation sequencing market. Buyers have to ensure suppliers have regional regulatory expertise, therapeutic, operational capability and innovative technologies to handle the complex trials. Upon assurance, a full-service strategic partnership could be formed.

    • The field of medicine is witnessing numerous tech advancements that are flourishing at a breakneck speed and have triggered the development of personalized drugs and medicine. NGS finds huge applications in personalized medicine, a trend setting high hopes for market players.


    Market Overview

    • Next Generation Sequencing Market Size Growth: Market Revenue (2017): 5.1 $Billion, CAGR growth rate: 19.5-20.5 percent by 2022.
    • Pricing Models used in the next generation sequencers market: Most Preferred: Fixed Unit Price and FFS, Alternate Models: Project-based, FTE, Time, and Materials.
    • Engagement model used in the next-generation sequencing market: Most Preferred: Project-based and Preferred Partnerships, Alternate Models: Strategic Partnerships.
    • NGS was outsourced at an approximate rate of 60–65 percent in 2017. It is mainly driven by high cost infrastructure and the expertise requirement for NGS services.
    • The major industry trends in the next generation sequencing market: Strategic partnership for data-driven solutions and end to end solutions to customers.
    • The regional revenue split in the global next-generation sequencing market: North America accounted for the largest share of the market in 2017 followed by Europe. Emerging Markets include: China, India, Eastern Europe.
    • Specialized sequencing service providers eye on large pharmaceutical firms as the volume of work by these firms are high, generating additional revenue and bringing in brand visibility. 


    Why You Should Buy This Report

    • The report gives details on the next generation sequencing market size, trends, growth drivers and constraints and the Porter’s five force analysis.
    • It gives information on the NGS platforms, top suppliers and sourcing, pricing and engagement models in the next-generation sequencing market. 
    • It provides a competitive intelligence report on the major industry cases and important deals between suppliers and buyers in the next generation sequencers market.